NOW APPROVEDLearn More
NOW APPROVEDLearn More
At Heron, we are unwavering in our commitment to improve the lives of patients. We aim to advance the therapeutic standard of care for patients through a portfolio of best-in-class therapies that bring together our innovative science and technologies with well-known pharmacology to deliver medicines that matter.
At Heron, we understand what is at stake for patients, their caregivers, and families, which is why we are laser-focused on providing solutions that can address unmet medical needs so they can spend more time doing the things that matter with the people who matter.
In the United States each year, 50 million surgeries are performed and the continuing over-reliance on postoperative opioids fuels the crisis by both exposing opioid-naïve patients to narcotics and by leaving hundreds of millions of leftover pills hiding in our community medicine cabinets.1-2Read More
Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard of care for acute care and oncology patients.
CINVANTI® for CINV:
U.S. FDA approved as both a 30-minute intravenous (IV) infusion and a 2-minute IV injection
ZYNRELEF® for Postoperative Pain Management:
Approved in the U.S., Canada and 31 European Countries
APONVIE™ for Postoperative Nausea and Vomiting (PONV):
U.S. FDA approved as a 30-second IV injection of aprepitant for PONV
At Heron, our mission is to improve the lives of patients by developing best-in-class medicines that address unmet medical needs. We are developing novel, patient-focused solutions that apply our innovative science and technologies to already-approved pharmacological agents.
February 28 2024
Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024Read More
January 24 2024
Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue ProceduresRead More
January 07 2024
Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative PainRead More
November 14 2023
Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial GuidanceRead More
Receive news and updates on Heron’s latest innovations.